Company Update: AbbVie Inc (NYSE:ABBV) – FDA warns of serious liver injury risk with Abbvie hep C drugs

[Reuters] – U.S. health regulators on Thursday issued a warning of potential risk of serious liver injury for certain patients using AbbVie’s hepatitis C treatments, Viekira Pak and Technivie, sending the drugmaker’s … . . . → Read More: Company Update: AbbVie Inc (NYSE:ABBV) – FDA warns of serious liver injury risk with Abbvie hep C drugs Similar Articles: Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015 Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie, Bristol-Myers get FDA nod for hep C treatments